BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 17902043)

  • 21. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?
    Liu W; Pfister EL; Kennington LA; Chase KO; Mueller C; DiFiglia M; Aronin N
    J Huntingtons Dis; 2016; 5(1):33-8. PubMed ID: 27003665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway.
    Ruan Q; Lesort M; MacDonald ME; Johnson GV
    Hum Mol Genet; 2004 Apr; 13(7):669-81. PubMed ID: 14962977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
    Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
    J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity.
    Khoshnan A; Ko J; Watkin EE; Paige LA; Reinhart PH; Patterson PH
    J Neurosci; 2004 Sep; 24(37):7999-8008. PubMed ID: 15371500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
    Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
    Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
    Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
    Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin improves the activity of the ubiquitin-proteasomal system in 150Q mutated huntingtin-expressing cells but exerts detrimental effects on neuronal survivability.
    Chakraborty J; Rajamma U; Jana N; Mohanakumar KP
    J Neurosci Res; 2015 Oct; 93(10):1581-91. PubMed ID: 26153070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How does the Huntington's disease mutation damage cells?
    Rubinsztein DC
    Sci Aging Knowledge Environ; 2003 Sep; 2003(37):PE26. PubMed ID: 13679594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3) has a key role in the mitochondrial dysfunction induced by mutant huntingtin.
    Sassone F; Margulets V; Maraschi A; Rodighiero S; Passafaro M; Silani V; Ciammola A; Kirshenbaum LA; Sassone J
    Hum Mol Genet; 2015 Nov; 24(22):6530-9. PubMed ID: 26358776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A molecular investigation of true dominance in Huntington's disease.
    Narain Y; Wyttenbach A; Rankin J; Furlong RA; Rubinsztein DC
    J Med Genet; 1999 Oct; 36(10):739-46. PubMed ID: 10528852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.